Status:
COMPLETED
A Study of LY3819469 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This is a 2-part study. In Part A, the main purpose is to evaluate the safety and tolerability of the study drug LY3819469 in healthy participants with high lipoprotein (a) \[Lp(a)\] levels. How the b...
Eligibility Criteria
Inclusion
- Female participants must not be able to get pregnant and male participants must agree to adhere to contraception restrictions
- Have a body mass index (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m²)
- For Part B, participants should be of first-generation Japanese origin
Exclusion
- Are currently participating in or completed a clinical trial within the last 30 days
- Are heavy alcohol drinkers or heavy cigarette smokers
- Have donated blood of more than 500 milliliters (mL) in the last 3 months
Key Trial Info
Start Date :
June 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 9 2022
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04914546
Start Date
June 14 2021
End Date
November 9 2022
Last Update
November 21 2022
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Altasciences Clinical Los Angeles, Inc
Cypress, California, United States, 90630
2
Clinical Pharmacology of Miami
Miami, Florida, United States, 33014
3
Qps-Mra, Llc
Miami, Florida, United States, 33143
4
Endeavor Clinical Trials
San Antonio, Texas, United States, 78229